Voyager Therapeutics Inc
VYGR
查看详细走势图
3.680USD
+0.140+3.95%
收盘 02/06, 16:00（美东）报价延迟15分钟
204.17M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.95%
5天
-5.64%
1月
-10.02%
6月
+14.29%
今年开始到现在
-6.36%
1年
-32.10%
查看详细走势图
TradingKey Voyager Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Voyager Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名56/392位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价15.00。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Voyager Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
极度看好
Voyager Therapeutics Inc亮点
亮点风险
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
业绩高增长
公司营业收入稳步增长，连续3年增长95.57%
业绩增长期
公司处于发展阶段，最新年度总收入80.00M美元
利润高增长
公司净利润处于行业前列，最新年度总收入80.00M美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值合理
公司最新PE估值-1.69，处于3年历史合理位
机构减仓
最新机构持股30.91M股，环比减少17.81%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值3.27M
分析师目标
根据
12
位分析师
强力买入
评级
15.000
目标均价
+301.07%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Voyager Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Voyager Therapeutics Inc简介
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
公司代码VYGR
公司Voyager Therapeutics Inc
CEOSandrock (Alfred)
网址https://www.voyagertherapeutics.com/
相关品种
